Who’s Going To Pay For Global Health?
The amazingly swift global response to the SARS outbreak earlier this year demonstrated once and for all that it is possible for countries to join forces and fight epidemics quickly and effectively. So, shouldn’t the same apply to the true pandemics � AIDS, malaria and tuberculosis? Indeed it should � but global strategies to fight these scourges are just now starting to come together.
Seeking a Prescription for Biogenerics
No U.S. laws allow for generic versions of off-patent biotech medicines. Several forces are now working to change that
Why Merck Missed the Mark
S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report and what the future may hold
Biotech: Teva’s Next Triumph?
The Israeli maker of generics wants a piece of the fast-growing bio-drug market
Gene Therapy Rebuilds Gums
Gene therapy can restore damage caused by severe gum disease, suggest animal studies.
Is Viagra Vulnerable?
Eli Lilly’s Cialis lasts for 36 hours–and a $100 million ad blitz will spread the word
It’s Wake-Up Time
Kiss your pillow good-bye. A new breed of drugs promises to do for drowsiness what Prozac did for depression.
Biotech plans: Boon or fantasy?
Having mapped hormones, synthesized molecules and discovered new cell receptors, the Scripps Research Institute wants to embark on one of its biggest cloning experiments: converting the Sunshine State into biotech beach by using $510 million from taxpayers.
REDISCOVERING NATURAL PRODUCTS
Cast aside for years, natural products drug discovery appears to be reclaiming attention and on the verge of a comeback
Biotech funding on track to bounce back
It’s not over yet, but 2003 already looks like a banner year for biotechnology funding in the United States, according to a survey released yesterday by the accounting firm Ernst & Young.